Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kumble S. Prabhu
Pennsylvania State University Univ Park, Department: Veterinary Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nemean Pharma Corporation
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The NIH project deals with the effect of pharmacological levels of omega-3 in the diet on leukemia progression. Although Dr. Prabhu will learn about some of the underlying mechanisms as to how metabolites of eicosapentaenoic acid (EPA) might target leukemia stem cells, as part of the NIH proposal, it may or may not have any overlap when the company considers other cancers (breast, colon, pancreatic) that is beyond the scope as far as the NIH grant is concerned. Thus, the primary potential for overlap could be in the goals that specify the mechanism of action. Moreover, the NIH-funded work could point to the efficacy of D12PGJ3 in other tumors, which could increase its value with the company.
Effect of Omega-3 Fatty Acids on Cancer Stem Cells
The application is based on a relatively understudied area of complementary and alternative medicine of omega-3 fatty acid, eicosapentaenoic acid (EPA), and its role in the targeting of cancer stem cells for apoptosis. Using a model of chronic myelogenous leukemia (CML), we hypothesize that some of the novel metabolites of EPA, in form of cyclopentenone prostaglandin J3 series, initiate apoptosis of leukemia stem cells that lead to CML.
Filed on August 06, 2015.
Tell us what you know about Kumble S. Prabhu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.